| LBCTR2020033438 | MO39171 | A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL) | A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL) | Interventional | Complete | 22/03/2020 |
| LBCTR2020030186 | MN39159 | Consonance | AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS | Interventional | Complete | 28/01/2019 |
| LBCTR2024015481 | ML44926 | LUNG Study | A Biomarker-Driven Precision Management of Lebanese Patients with Previously Untreated Metastatic Non-Squamous Non-Small Cell LunG Cancer | Interventional | Pending | 19/08/2024 |
| LBCTR2023075403 | MK7-003 | ViKEM | Vitamin K2 Supplementation in Adult Episodic Migraine | Interventional | Pending | 24/07/2023 |
| LBCTR2020113522 | MERS-201 | Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers | Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Healthy Volunteers | Interventional | Complete | 28/06/2020 |
| LBCTR2020073458 | MEQ00063 | A Phase III, open-label, study to describe the immunogenicity and safety of MenACYW conjugate vaccine in potential pilgrims ≥ 56 years of age in Turkey and Lebanon. | A Phase III, open-label, study to describe the immunogenicity and safety of MenACYW conjugate vaccine in potential pilgrims ≥ 56 years of age in Turkey and Lebanon. | Interventional | Other | 30/07/2020 |
| LBCTR2018120171 | MB02-C-02-17 | A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) | A Randomized, Multicenter, Multinational, Double-Blind Study to Assess the Efficacy and Safety of MB02 (Bevacizumab Biosimilar Drug) Versus Avastin® in Combination With Carboplatin and Paclitaxel for the Treatment of Subjects With Stage IIIB/IV Non-squamous Non-Small Cell Lung Cancer (NSCLC) | Interventional | Complete | 18/11/2020 |
| LBCTR2020033434 | MA30143 | AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS | AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS | Interventional | Complete | 19/03/2020 |
| LBCTR2019040212 | LPS15396 | A multicenter, multinational, prospective, interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin | A multicenter, multinational, prospective, interventional, single-arm, Phase IV study evaluating the clinical efficacy and safety of 26 weeks of treatment with insulin glargine 300 U/mL (Gla-300) in patients with Type 2 diabetes mellitus uncontrolled on basal insulin | Interventional | Other | 15/03/2019 |
| LBCTR2019010169 | LPI-JOR-LEB-KSA-TUN-2017-01 | Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia | Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia | Interventional | Recruiting | 24/10/2018 |